A blank-check company seeking to combine with a health care business that has the capacity to develop new drug therapies and technologies told regulators Thursday it plans to raise $200 million in an initial public offering guided by Kirkland and Ellenoff Grossman.
While the rapid growth of e-commerce has generated much buzz around a robust logistics property market as retailers gobble up distribution space, life sciences real estate is also booming, and experts say the sector has the potential to outlast logistics and remain attractive for some time. Here are three things to watch amid the life sciences boom.
A Kentucky federal judge refused to block Catalent Pharma Solutions Inc. from importing a key ingredient of the anti-epileptic drug Vimpat, saying the company is protected by a safe harbor provision of the Hatch-Waxman Act.
Moderna's appeal of a Patent Trial and Appeal Board ruling that upheld an Arbutus patent for drug-delivery composition should be rejected because it is based on Moderna's "imagined legal error," the Federal Circuit was told.
Life sciences software and analytics business Axtria said Thursday it landed $150 million in funding from Bain Capital Tech Opportunities, which it will use to expand its software-as-a-service products.
A bummed-out California judge on Wednesday lambasted loquacious lawyers for handling the nation's second opioid crisis trial at a decidedly West Coast clip, declaring that they've been "wasting time" with irrelevant inquiries during four weeks of increasingly tedious testimony.
A University of North Carolina biology professor, speaking as an expert witness on behalf of a clinic and two doctors being sued by the government over experimental stem cell treatments, told a California federal judge on Wednesday that the treatment is so safe she received it herself.
Medical device company Flowonix Medical Inc. has accused a former sales employee of breaking a noncompete and nonsolicitation agreement when he made the move to competitor Medtronic.
A federal judge said Wednesday horseshoe crabs cannot be commercially harvested from a national wildlife refuge in South Carolina to benefit a pharmaceutical company, ruling in favor of an environmental group that argued the federal government improperly authorized the activity.
A Florida federal judge ruled Wednesday that Adventist Health System can collect about $1.5 million after a California-based asset management firm defaulted on a settlement agreement they reached to resolve the hospital operator's fraud suit over a failed $57.5 million deal for personal protective equipment.
U.S. Trade Representative Katherine Tai defended her office's endorsement of a temporary waiver of intellectual property protections for COVID-19 vaccines Wednesday as skeptical senators expressed their discontent with the decision.
The Second Circuit on Wednesday denied an appeal by patients alleging that Pfizer Inc.'s former cholesterol drug Lipitor gave them Type 2 diabetes, agreeing with the trial court's decision that their claims were either federally preempted or filed too late.
The Rosen Law Firm PA has been appointed to lead a consolidated securities suit in Delaware federal court claiming Walmart misled investors about its part in the opioid epidemic, with Farnan LLP to serve as liaison counsel in the proposed class action.
Private equity firm Clayton Dubilier & Rice LLC said Wednesday it was buying health care advisory and pharmaceutical services business UDG for £2.6 billion (about $3.7 billion) in a deal led by five law firms including Clifford Chance and Freshfields.
A New York bankruptcy judge on Wednesday approved a motion setting an August date for Purdue Pharma's Chapter 11 plan confirmation hearing, assuming the drugmaker's plan disclosure statement is approved next week.
Walmart Inc. has asked the Fifth Circuit to resurrect its lawsuit against the U.S. Department of Justice in which the retail giant sought a declaration that its prescription opioid sales are lawful, arguing that pre-enforcement review is a standard route for entities looking to clarify the scope of the law without waiting to be sued.
Hartford Fire Insurance Co. is suing medical supplier Medline Industries in Illinois federal court, arguing that it doesn't need to defend a putative class action alleging the supplier released a toxic chemical into the air in two cities north of Chicago.
A U.S. Food and Drug Administration investigator told a California federal judge Tuesday about deficiencies she noted at a clinic being sued by the government over experimental stem cell treatments, including a lack of central documentation on adverse events such as a patient suffering retinal detachment after receiving eye injections.
Before Theranos founder Elizabeth Holmes and her ex-boyfriend were charged with deceiving investors and patients about their blood-testing technology's efficacy, the pair exchanged voluminous text messages that now threaten to provide jurors at Holmes' criminal trial this summer a rare window into her psyche.
U.S. senators on Tuesday approved the confirmation of Andrea Palm to serve as deputy secretary for the U.S. Department of Health and Human Services.
A class of Tesaro stockholders seeking damages for an allegedly underpriced $5.1 billion sale of the cancer drugmaker in 2018 came to Chancery Court with a suit "heavy on innuendo and speculation" but short of facts, an attorney for the company's board told a Delaware vice chancellor Tuesday.
The Federal Circuit on Tuesday upheld a jury verdict that DNA analysis patents Pacific Biosciences asserted against Oxford Nanopore Technologies Inc. are invalid for lack of enablement, rejecting PacBio's argument that Oxford used fearmongering over COVID-19 to pull off a win.
A California federal judge dismissed an amended suit brought by a spouse looking to hold her husband's employer responsible for her COVID-19 infection, finding that the state's workers' compensation law bars her argument and further noting that the employer's duty to provide a safe work environment does not extend to non-employees.
A Florida federal judge on Tuesday excluded opinions from one of 3M's expert witnesses in an upcoming bellwether trial over whether its combat arms CAEv2s earplugs were defective and caused damage to a veteran's hearing, saying the expert cannot base his opinion entirely on other experts' findings.
A Democratic member of the Federal Trade Commission skewered what he considers the agency's lax view toward confronting Big Pharma mergers to prevent possible antitrust violations, calling Tuesday for an aggressive new enforcement approach to the industry.
False Claims Act recoveries were modest overall in 2020, but the relatively calm year seeded the clouds for a stormy 2021 by generating tremendous government spending on pandemic relief, a record number of new cases and a potentially game-changing decision in a closely watched area of Medicare fraud litigation.
Health care and life sciences lawyers are heading into an electrifying year of litigation as the Trump administration's 11th-hour policymaking sparks legal challenges, the coronavirus pandemic ignites fraud suits, fodder grows for kickback probes and the U.S. Supreme Court mulls momentous cases involving the False Claims Act, abortion and Obamacare.
The U.S. Department of Health and Human Services accused Gilead Sciences Inc. on Wednesday of infringing four agency patents covering the use of HIV treatment medication to prevent infection, escalating a fight that has been brewing for months.
Given the lack of know-how and other legal and technical hurdles associated with producing COVID-19 vaccines in developing countries, and the potential harm to U.S. industry, the Biden administration's backing of a temporary waiver on intellectual property protections may be merely a gesture of goodwill, says William Bergmann at BakerHostetler.
False advertising class action plaintiffs often target language from a defendant's marketing materials or product label — but a defendant may be able to challenge class certification with evidence that many class members did not see the statement in question, say Michael Schwartz and Maren Messing at Patterson Belknap.
A Massachusetts federal judge’s recent rebuke of the state Attorney General’s Office for refusing to respond to discovery requests in Alliance for Automotive Innovation v. Healey highlights six important considerations for attorneys who want to avoid the dreaded benchslap, say Alison Eggers and Dallin Wilson at Seyfarth.
Following the D.C. Circuit’s recent notice discouraging use of the font Garamond in legal briefs, Jason Steed at Kilpatrick looks at typeface requirements and preferences in appellate courts across the country, and how practitioners can score a few extra brief-writing points with typography.
Joseph Berger and Thomas Mason at Thompson Hine examine the significant opportunities for government contractors arising from actions during the first 100 days of the Biden administration, which set the stage for unprecedented investment in national infrastructure, domestic manufacturing, research and development, clean energy, pandemic response and economic recovery.
The U.S. Supreme Court should hear Janssen Pharmaceuticals v. AY, and rule that drugmakers are not required to include off-label warnings, in order to protect companies from being held liable for failing to do what federal law prohibits, say Sheldon Bradshaw and Lisa Dwyer at King & Spalding.
As the legal industry continues to change in the post-pandemic world, law firms should adapt to client demands by constantly measuring and managing the profitability of their services, says Joseph Altonji at LawVision.
The Federal Circuit recently employed a flexible standard for constructing Olaplex's hair care patent claims in a case against L'Oreal, but more precise claim drafting could have avoided altogether a problem with claims for component amounts in product formulations, says Philip Hamzik at Wolf Greenfield.
Recent rulings shed light on how courts and international arbitration tribunals decide if litigation funding materials are discoverable and reaffirm best practices that attorneys should follow when communicating with funders, say Justin Maleson at Longford Capital and Michele Slachetka and Christian Plummer at Jenner & Block.
The U.S. Supreme Court's decision in AMG Capital v. Federal Trade Commission, limiting the agency's ability to seek equitable monetary relief under the FTC Act, will likely also restrain the U.S. Food and Drug Administration's authority under the Federal Food, Drug, and Cosmetic Act, due to similarities between the laws, say Joshua Oyster and Jenna McCarthy at Ropes & Gray.
Employers can expect more actions against wage-fixing or no-poach agreements as the U.S. Department of Justice's Antitrust Division cracks down on labor market collusion, so companies should consider tailoring these agreements on their scope, duration and definition of nonsolicitation, say attorneys at Duane Morris.
New amendments to the West Virginia Consumer Credit and Protection Act will help businesses in the state, particularly in the financial services industry, by better defining the process for presuit notice and opportunity to cure, and by making it easier to recover attorney fees, say Andrew Narod and Jared Searls at Bradley Arant.
Well-grounded scientific testimony in judicial proceedings has become more essential than ever, especially with large verdicts at stake in cases concerning hot-button issues like talc and climate change, so judges must act as gatekeepers to exclude unsound science from jury trials, says Lawrence Ebner at the Atlantic Legal Foundation.
The Federal Circuit's recent holding in Bio-Rad v. International Trade Commission, that an assignment clause wasn’t enough to claim patent ownership where the conception date followed former inventors’ employment, shows companies and workers the importance of specificity in drafting contractual limitations, say Bryan Vogel and Derrick Carman at Robins Kaplan.
Resolution of the legal uncertainty presented by the dueling federal and state approaches to cannabis will pave the way for legal cannabis businesses to access the insurance protections the industry needs for everything from workers' compensation to auto insurance to general liability, says Christy Thiems at the American Property Casualty Insurance Association.